MEDAREX! - 500 Beiträge pro Seite

[oppaduska]

jetzt schon bei 74!

jetzt eröffnet usa, eventuell nochmal ganz kurz runter, dann geht es nach der info der kooperationen steil bergauf.

anderer meinung?

[Schmuxa]

Hallo,

welche Kooperation?
Wolln wirs hoffen, daß es steil bergauf geht!


Gruß
schmuxa

[MrGruendlich]

Welche info ???????



MfG MrGruendlich

[EuroBoy]

Medarex and Corixa Form Alliance to Discover and Develop Therapeutic Monoclonal Antibodies

PRINCETON, N.J. and SEATTLE, June 7 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX), a biopharmaceutical company, and Corixa Corporation (Nasdaq: CRXA), a research and development-based biotechnology company, today announced a collaboration to discover and develop fully human monoclonal antibodies against selected targets from Corixa`s library of proprietary autoimmune disease, cancer and infectious disease antigens.

Corixa intends to contribute three targets initially and up to six or more targets a year during the term of the agreement. Medarex will contribute its HuMAb-Mouse(R) technology to the multi-year collaboration, targeted to generate, screen and characterize fully human monoclonal antibodies directed against Corixa`s antigens. Corixa, and in some cases Medarex, will then be responsible for determining whether the characterized antibodies have an immunotherapeutic effect in tissue culture experiments and in animal models of human disease.

When antibodies are jointly determined to be worthy of clinical investigation, Corixa and Medarex will hold a closed auction between the two parties for the rights to develop the specific antibody-based product. The company with the winning bid will pay the bid amount in cash to the other company and will be responsible at that point in time for all product development and commercialization expenses and decisions. The other company will receive future product development milestone payments and royalties on future product sales.

"We look forward to a fruitful partnership that will combine Corixa`s expertise in antigen discovery with our HuMAb-Mouse technology," said Donald L. Drakeman, President and Chief Executive Officer of Medarex. "This relationship could present Medarex with the opportunity to add to our own product development pipeline or benefit from products developed by Corixa. This partnership is another example of Medarex`s powerful technology base, which continues to evolve and offer our partners the benefits of high-affinity fully human antibodies."

"We are pleased to be working with Medarex in a joint effort to develop fully human monoclonal antibody based therapeutics. We are impressed with Medarex`s growing technology base in the generation of fully human monoclonal antibodies," said Steven Gillis, Ph.D., Chairman and Chief Executive Officer of Corixa. "Our proprietary tumor antigen discovery efforts have led to identification of multiple, novel, cell-surface proteins that could prove useful as targets for therapeutic antibody development. In recent months we have intensified efforts in infectious disease antigen discovery and will continue to explore identification of antigens in autoimmune diseases where antibody therapy might prove beneficial in either stopping or reversing the disease process. The breadth of our antigen portfolio places us in the position of being able to develop antibodies with several partners. The addition of Medarex as a commercial collaborator represents another example of our Powered by Corixa(TM) approach targeting the presence of some element of Corixa`s technology in as many novel, immunotherapeutic products as possible."

The collaboration will be managed by a joint steering committee made up of representatives from both companies. The steering committee will be responsible for acceptance of Corixa antigens into the partnership, resource allocation, and determination of which resultant antibodies are available for auction. About Corixa

Corixa is a research- and development-based biotechnology company committed to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary vaccine components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals and diagnostics, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, Wash., with additional operations in Hamilton, Mont. and Redwood City, Calif. For more information, please visit Corixa`s website at http://www.corixa.com or call the company`s investor relations information line at 1-877-4CORIXA or 1-877-426-7492. About Medarex

Medarex is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. Medarex has assembled a broad platform of patented technologies for antibody discovery and development, including the HuMAb-Mouse and TC Mouse(TM) systems for the creation of high-affinity, fully human antibodies. Using standard, well proven laboratory techniques, scientists can produce these fully human antibodies in a matter of months. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody development capabilities, including pre-clinical and clinical manufacturing services. For more information about Medarex visit its web site at http://www.medarex.com . Forward-Looking Statements

Except for the historical information presented, certain matters discussed in this press release are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Such risks and uncertainties include risks associated with product discovery and development as well as risks detailed from time to time in the companies` public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including each company`s Annual Report on Form 10-K for the fiscal year ended December 31, 1999, and Corixa`s Amended Registration Statement on Form S-3, filed on April 7, 2000. Copies of public disclosure filings with the Securities and Exchange Commission (SEC) are available from each company`s investor relations department.


/CONTACT: Donald L. Drakeman, President and CEO of Medarex, Inc., 609-430-2880; or Kimberly Hofman of Middleberg Euro RSCG, 212-888-6610, ext. 544, or [e-mail], for Medarex, Inc.; or Jim DeNike, Investor Relations of Corixa Corporation, 206-754-5716, or [e-mail]; or Jesse Ciccone of FitzGerald Communications, Inc., 415-986-9500, or [e-mail], for Corixa/